Big bull stocks Aba Chemicals Corporation(300261) , which once soared four times, fell 44% after the Spring Festival.
On February 11, Aba Chemicals Corporation(300261) fell by 13.07% again and once fell to 17% in the session. As of the closing, the stock was reported at 15.3 yuan, with a total market value of 14.7 billion yuan.
5 trading days fell 44%
Due to the abnormal fluctuation of the stock price, Aba Chemicals Corporation(300261) was suspended from January 17 and resumed from the opening of the market on February 7. However, on the first trading day after the Spring Festival, that is, February 7, Aba Chemicals Corporation(300261) opened directly to the word limit, opening the slump mode. On February 8, Aba Chemicals Corporation(300261) fell 17.66% again. Just after easing on February 9, it fell again for two consecutive days on February 10 and 11.
In other words, only five trading days after the festival, Aba Chemicals Corporation(300261) has fallen by 44% and its market value has shrunk by 11.6 billion yuan. The former 4-fold bull stocks have become one of the worst A-share stocks in the year of the tiger.
various funds fled one after another
With the flameout of covid-19 oral drug concept, various funds fled one after another. According to the public trading information released by the Shanghai and Shenzhen Stock Exchange on February 8, Aba Chemicals Corporation(300261) was listed on the dragon and tiger list due to the daily price decline of - 17.66% and the cumulative deviation from the price decline during the abnormal period of - 36.58%. This is the third time in the last five trading days.
The list shows that the total net sales of the top five seats are 236812200 yuan, and top hot money appears. Among them, the sales amount of the business department of China Industrial Securities Co.Ltd(601377) Shaanxi Branch is 113 million yuan.
The total net purchase of the top five seats was 96.7461 million yuan, while the second business department of China stock market news securities Lhasa East Ring Road occupied one seat, with a net purchase of 17.3787 million yuan on the same day.
Aba Chemicals Corporation(300261) soared 440%
high position reduction of actual controller
Due to the influence of covid-19 oral drug concept, Aba Chemicals Corporation(300261) since November last year, the share price has soared continuously, from 5 yuan / share to 27.32 yuan / share, with a cumulative increase of 440% during the period.
It is worth noting that after the sharp rise in the stock price, Wang Xinya, one of the actual controllers of Aba Chemicals Corporation(300261) , reduced 19 million shares through block trading on November 30, 2021, accounting for 1.97%, with a reduction amount of about 138 million yuan.
Aba Chemicals Corporation(300261) clarify again: has not signed a cooperation agreement with Pfizer
Due to the abnormal fluctuation of the company's stock trading, Aba Chemicals Corporation(300261) frequently received letters of concern and repeatedly issued announcements of suspension and verification.
In the letter of concern, the Shenzhen Stock Exchange asked Aba Chemicals Corporation(300261) to explain whether the company violates fair information disclosure and is easy to cater to market hot spots and hype stock prices through interaction. At the same time, explain whether it is suspected to use the media's information about Pfizer covid-19 oral medicine's possible indirect use of carbonic anhydride to raise investor expectations and cooperate with speculation in the company's share price.
On January 28, Aba Chemicals Corporation(300261) replied to the letter of concern from the Shenzhen Stock Exchange, saying that up to now, the company has mainly supplied carone anhydride and its derivatives to six customers. As of January 27, the company's orders for carbonic anhydride and its derivatives were 62.1506 million yuan, with sales of 23.4116 million yuan in the current month.
It is worth noting that Aba Chemicals Corporation(300261) changed its words this time and said that carbonic anhydride and its derivatives are antiviral intermediates, which may be used for the R & D, synthesis or trade of downstream products after customers purchase. Carbonic anhydride and its derivatives refer to compounds, not specifically the products produced by the company. It is impossible to determine that the carbonic anhydride and its derivatives produced by the company can be used to synthesize Pfizer covid-19 oral medicine.
For Pfizer's cooperation, Aba Chemicals Corporation(300261) once again said that the company had not signed a cooperation agreement with Pfizer, had not supplied carlon anhydride products to Pfizer, and Pfizer had not provided the company with any quality standards for the purchase of covid-19 oral drug front-end raw materials. The company has repeatedly tried to communicate with customers about the end use of its purchasing company carbonic anhydride and its derivatives, but they were rejected by customers.
In terms of production expansion, Aba Chemicals Corporation(300261) said that the production expansion of carbonic anhydride and its derivatives has not been decided yet, and there is still great uncertainty in the final decision. When the downstream market situation of carbonic anhydride and its derivatives becomes clear, the company will make planning and prudent decision on whether to expand production.
Previously, Aba Chemicals Corporation(300261) disclosed the performance forecast for 2021. The company expects the net profit attributable to shareholders of Listed Companies in 2021 to be 180 million yuan to 200 million yuan, with a year-on-year increase of 11.79% - 24.21%, and the net profit after deducting non recurring profits and losses is expected to be 142 million yuan to 162 million yuan.
However, after the year, the covid-19 detection sector performed poorly. On February 11, the covid-19 detection index fell by 4.68%. In terms of individual stocks, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) , Andon Health Co.Ltd(002432) , Beijing Hotgen Biotech Co.Ltd(688068) all fell by more than 9%. In addition, Medicalsystem Biotechnology Co.Ltd(300439) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Thalys Medical Technology Group Corporation(603716) all fell.
